Amgen's monthly gain underperformed the Medical sector's gain, while operating in the biomedical and genetics industry.
2 reports, 0 independent
Updated Jul 3
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amgen's monthly gain underperformed the Medical sector's gain, while operating in the biomedical and genetics industry.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Incepta Pharmaceuticals
incepta
Related events
- GSK and Amgen are major biopharma players.
- Joint drug trial success boosts Amgen stock.
- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
- Amgen Inc. trades on the NASDAQ stock exchange.
- The biotech sector is experiencing a downturn due to drug failures, impacting companies like Amgen and Eli Lilly.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet